Medications for National Rare Diseases Program

This tender is for the procurement of medications under the National Rare Diseases Program, as per the attached technical specifications. The estimated quantities for the 24-month period are specified: a minimum of 960 vials and a maximum of 1,152 vials of 'vimizim'. Vimizim (elifigrastim) is a medication used to treat specific lysosomal storage disorders, such as Morquio syndrome A. This procurement is critical for ensuring that patients suffering from rare diseases have access to essential, often life-saving, treatments. The quantities indicate a defined patient population or treatment protocol. The tender aims to secure a reliable and timely supply of these specialized medications, adhering to the program's requirements and ensuring patient welfare. Further details on delivery, quality, and specific contract conditions are available in the technical documentation.

This is a supplies contract in the health and medical services sector, with a focus on Pharmaceuticals. Located in Romania, Europe, this opportunity is open to firms and consortiums.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.